A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND

他克莫司与类固醇和类固醇的随机、多中心比较试验

• 批准号: 7718010
• 负责人: ROBERT Bruce ETTENGER
• 金额: $ 0.71万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718010
• 关键词: Biological Availability; Childhood; Computer Retrieval of Information on Scientific Projects Database; Daclizumab; Enrollment; Funding; Grant; Immunosuppression; Institution; Kidney Transplantation; Mycophenolate Mofetil/Tacrolimus; Prograf; Protocols documentation; Randomized; Research; Research Personnel; Resources; Roche brand of daclizumab; Safety; Source; Steroids; Tacrolimus; Therapeutic immunosuppression; Transplant Recipients; United States National Institutes of Health; base; comparative trial; mycophenolate mofetil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: The primary objective of this protocol is to compare the safety and efficacy of steroid-free immunosuppression, given in combination with tacrolimus (Prograf), mycophenolate mofetil (CellCept) and daclizumab (Zenapax) induction with steroid-based immunosuppression. The specific aim of the tacrolimus/MPA PK sub-study is to determine the bioavailability of tacrolimus and mycophenolate mofetil in pediatric renal transplant patients enrolled in Protocol SNS01.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 具体目标： 该方案的主要目的是比较与他克莫司 (Prograf)、霉酚酸酯 (CellCept) 和达克珠单抗 (Zenapax) 联合使用的无类固醇免疫抑制与基于类固醇的免疫抑制的安全性和有效性。 他克莫司/MPA PK 子研究的具体目的是确定他克莫司和吗替麦考酚酯在纳入 SNS01 方案的儿童肾移植患者中的生物利用度。